Literature DB >> 10722493

Antiviral properties of a series of 1,6-naphthyridine and 7, 8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus.

J Bedard1, S May, L L'Heureux, T Stamminger, A Copsey, J Drach, J Huffman, L Chan, H Jin, R F Rando.   

Abstract

A series of 1,6-naphthyridine (L. Chan, H. Jin, T. Stefanac, J. F. Lavallee, G. Falardeau, W. Wang, J. Bedard, S. May, and L. Yuen, J. Med. Chem. 42:3023-3025, 1999) and isoquinoline (L. Chan, H. Jin, T. Stefanac, W. Wang, J. F. Lavallee, J. Bedard, and S. May, Bioorg. Med. Chem. Lett. 9:2583-2586, 1999) analogues exhibiting a high level of anti-human cytomegalovirus (HCMV) activity were investigated in a series of studies aimed at better understanding the mechanism of action of some representatives of this class of compounds. In vitro antiviral profiling revealed that these compounds were active against a narrow spectrum of viruses, essentially the human herpesviruses and type 2 rhinovirus. In HCMV assays, a 39- to 223-fold lower 50% inhibitory concentration was obtained for compound A1 than for ganciclovir against strains AD 169 and Towne. In addition, ganciclovir, foscarnet, cidofovir, and BDCRB (2-bromo-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole)-resistant HCMV strains remained susceptible to 1,6-naphthyridines and 7, 8-dihydroisoquinolines tested in this study, supporting the view that a novel mechanism of action could be involved. Drug combination studies showed a small but significant synergistic antiviral effect between compound B2 and ganciclovir. Cytotoxicity profiling of representative compounds under various cell growth conditions indicated a generally similar cytotoxic effect, relative to ganciclovir, in log-phase growing cells. However, in stationary cells, a relatively higher level of toxicity was observed than that for control compound. Effect of time of drug addition showed that the anti-HCMV activity of compound A1, ganciclovir, and cidofovir was lost at approximately the same time (72 h postinfection), indicating that the compound was affecting events at the early and late stage of virus replication. This interpretation is also supported by reduction of de novo synthesis of pp65 tegument protein and lack of any effect of the compound on viral adsorption. A reduction of the HCMV enhancer-promoter-directed luciferase expression was also observed in a stably transfected cell line when compound A1 was present at relatively high concentrations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722493      PMCID: PMC89794          DOI: 10.1128/AAC.44.4.929-937.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

Review 1.  A three-dimensional model to analyze drug-drug interactions.

Authors:  M N Prichard; C Shipman
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

Review 2.  Infection in bone marrow transplant recipients.

Authors:  J D Meyers
Journal:  Am J Med       Date:  1986-07-28       Impact factor: 4.965

3.  A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus.

Authors:  M N Prichard; S R Turk; L A Coleman; S L Engelhardt; C Shipman; J C Drach
Journal:  J Virol Methods       Date:  1990-04       Impact factor: 2.014

Review 4.  Human cytomegalovirus: challenges, opportunities and new drug development.

Authors:  A K Field
Journal:  Antivir Chem Chemother       Date:  1999-09

5.  Death in the AIDS patient: role of cytomegalovirus.

Authors:  A M Macher; C M Reichert; S E Straus; D L Longo; J Parrillo; H C Lane; A S Fauci; A H Rook; J F Manischewitz; G V Quinnan
Journal:  N Engl J Med       Date:  1983-12-08       Impact factor: 91.245

6.  Isoquinoline-6-carboxamides as potent and selective anti-human cytomegalovirus (HCMV) inhibitors.

Authors:  L Chan; H Jin; T Stefanac; W Wang; J F Lavallée; J Bédard; S May
Journal:  Bioorg Med Chem Lett       Date:  1999-09-06       Impact factor: 2.823

Review 7.  Cytomegalovirus and the acquired immunodeficiency syndrome.

Authors:  A S Tyms; D L Taylor; J M Parkin
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

8.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

Review 9.  Concomitant ganciclovir and zidovudine treatment for cytomegalovirus retinitis in patients with HIV infection: an approach to treatment.

Authors:  D Causey
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

Review 10.  Prevention and treatment of cytomegalovirus infection.

Authors:  J D Meyers
Journal:  Annu Rev Med       Date:  1991       Impact factor: 13.739

View more
  7 in total

1.  Effect of specific solute-solvent interaction and electron donor-acceptor substituents of novel pyrazolo naphthyridines on fluorescence.

Authors:  Sandeep R Patil; Deepak P Shelar; Ramhari V Rote; Raghunath B Toche; Madhukar N Jachak
Journal:  J Fluoresc       Date:  2010-09-30       Impact factor: 2.217

2.  Ganciclovir and cidofovir treatment of cytomegalovirus-induced myocarditis in mice.

Authors:  J C Lenzo; G R Shellam; C M Lawson
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 3.  Greener organic synthetic methods: Sonochemistry and heterogeneous catalysis promoted multicomponent reactions.

Authors:  Ingrid V Machado; Jhonathan R N Dos Santos; Marcelo A P Januario; Arlene G Corrêa
Journal:  Ultrason Sonochem       Date:  2021-08-05       Impact factor: 7.491

4.  N-(1-Naphth-yl)-10H-9-oxa-1,3-diaza-anthracen-4-amine.

Authors:  Hoong-Kun Fun; Suchada Chantrapromma; Sankappa Rai; Prakash Shetty; Arun M Isloor
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-02-13

5.  2,9-Dimethyl-7-phenyl-N-(4-methyl-phen-yl)dibenzo[b,h][1,6]naphthyridin-6-amine.

Authors:  K N Vennila; M Manoj; K Prabha; K J Rajendra Prasad; D Velmurugan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-12-11

6.  7-(4-Meth-oxy-phen-yl)-4,9-dimethyl-N-(4-methyl-phen-yl)-5,12-diaza-tetra-phen-6-amine.

Authors:  K N Vennila; K Prabha; K J Rajendra Prasad; D Velmurugan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-03-02

7.  7-(2-Chloro-phen-yl)-2,6,9-trimethyl-dibenzo[b,h][1,6]naphthyridine.

Authors:  K N Vennila; K Prabha; M Manoj; K J Rajendra Prasad; D Velmurugan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.